{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol acetate
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Ametantrone (AM) is a synthetic 9,10-anthracenedione bearing two (hydroxyethylamino)ethylamino residues at positions 1 and 4; along with other anthraquinones and anthracyclines, it shares a polycyclic intercalating moiety and charged side chains that stabilize DNA binding. Ametantrone is anticancer drug candidate targeting DNA. Ametantrone is a topoisomerase II inhibitor of the anthrapyrazole family. Ametantrone induces interstrand DNA cross-links in HeLa S3 cells. These cross-links were observed only in cellular system suggesting that metabolism of the drugs is a necessary step leading to DNA cross-linking. Ametantrone appeared to be very well tolerated and easy to handle. A dose-schedule of 135 mg/m2 q 2–3 weeks was recommended for phase II studies in solid tumors.
Status:
Investigational
Source:
NCT01097018: Phase 3 Interventional Completed Colorectal Cancer
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Perifosine is an orally active alkyl-phosphocholine compound with potential antineoplastic activity. Perifosine is an Akt inhibitor, which targets the pleckstrin homology domain of Akt, thereby preventing its translocation to the plasma membrane. Perifosine exerts Akt-dependent and Akt-independent effects, and although many preclinical studies have documented Akt inhibition by perifosine, clinical validation of these findings is lacking. Perifosine is in phase II and III clinical trials for the treatment of neuroblastoma, glioblastoma multiforme and other solid tumors.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cismadinone is a progestogen steroid.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cistinexine is an expectorant drug developed by Italian company Recordati S.p.A. Cistinexine as a cystine derivative that has shown an expectorant action similar to bromhexine during preclinical pharmacological trials. In clinical trials in patients with chronic bronchitis, treatment with cistinexine did not lead to a reduction of mucus transport rate (MTR). The only significant effect was observed in patients with severe impairment of MTR.
Status:
Investigational
Source:
NCT00048022: Phase 2 Interventional Completed Asthma
(2002)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Valategrast (R-411) is a dual-acting α4/β1 - α4/β7 integrin antagonist which underwent clinical development with Roche for the treatment of multiple sclerosis (MS) and asthma. Phase I and II studies have been
conducted. It had shown good efficacy in animal disease models. Following oral administration, R-411 was rapidly
and completely biotransformed into its active metabolite, RO-0270608, most of which was eliminated by biliary excretion. R-411 had shown acceptable pharmacokinetics and
good safety in healthy volunteers. R-411 inhibited eosinophil and T H 2 cell excitation and survival, and inhibited eosinophil migration from blood to pulmonary tissues. The idea of combining R-411 with montelukast (leukotriene antagonist) in the pharmaceutical dosage
forms, therefore, provided a therapeutic treatment that had the combined effect of reducing circulating eosinophil counts
and reducing eosinophil egress into pulmonary tissues, thereby providing an early onset of bronchodilation as well as sustained anti-inflammatory effects. Valategrast had been in phase II clinical trials by Roche for the treatment of asthma and in phase I clinical trials for the treatment of multiple sclerosis (MS). However, the study had been discontinued. Development of Valategrast was
discontinued for the treatment of asthma after clarification of the regulatory framework for that class of compounds.
Status:
Investigational
Source:
INN:fepentolic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
FEPENTOLIC ACID is a choleretic agent.
Status:
Investigational
Source:
INN:fenpipramide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
FENPIPRAMIDE is a parasympatholytic agent. As a hydrochloride salt, it is an active ingredient of some veterinary medicinal products used as analgesic drugs or antidotes. FENPIPRAMIDE was formerly used in humans as a spasmolytic in obstetrics.
Class (Stereo):
CHEMICAL (MIXED)
Etanterol (VAL 481), a phenethanolamine derivative, is a β2 adrenoceptor agonist that was undergoing phase II trials in Italy as a bronchodilator with Valeas.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Pyrinoline is a substituted 2,3-dicarboximide patented by McNeil Laboratories, Inc. for the treatment of cardiac arrhythmias.
Class (Stereo):
CHEMICAL (ACHIRAL)
Cinuperone is an antagonist of D2, alpha1 adrenergic and sigma receptors. The drug selectively inhibits dopamine agonists-dependent behaviors, mediated by the limbic system. The clinical development of the drug as an antipsychotic was terminated due to orthostasis.
